This program supports research leading to the development of novel pharmacological treatments for childhood-onset mental disorders. Of interest is research on neurochemical and other molecular processes associated with these disorders, as well as pilot studies and early efficacy trials of novel pharmacological agents. Also of interest are the development of reliable and stable biomarkers, including biomarkers that can identify at-risk individuals prior to disease onset; indicators of treatment response or drug safety; measures of disease progression; and markers that identify CNS abnormalities.
Margaret C. Grabb, Ph.D.
6001 Executive Boulevard, Room 7203, MSC 9645